Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome.

Kim, Hawk

Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. [electronic resource] - British journal of haematology 09 2019 - e151-e155 p. digital

Publication Type: Letter; Research Support, Non-U.S. Gov't

1365-2141

10.1111/bjh.15991 doi


Angiogenesis Inhibitors--pharmacology
Female
Humans
Lenalidomide--pharmacology
Male
Myelodysplastic Syndromes--drug therapy
Prognosis
Progression-Free Survival
Survival Analysis